Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

摘要

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing an assisted reproductive technology. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation.